AV-101 / L-4-Chlorokynurenine Has any supplier looked into this? Neuroprotective, anticonvulsant, anti-depressant in multiple ways.

https://en.wikipedia.org/wiki/4-Chlorokynurenine

L-4-Chlorokynurenine (4-Cl-KYN, developmental code name AV-101) is an orally active small molecule prodrug candidate that in vivo produces a glycine binding site NMDA receptor antagonist. AV-101 is in clinical development by VistaGen Therapeutics. Inc. as a potential new generation, fast-acting antidepressant,[1][2] and for other central nervous system (CNS) indications. The initial Phase 2 clinical study of AV-101 is expected to begin in 2015 and will be focused on treatment-resistant depression (TRD) and major depressive disorder (MDD).[3]

Neuroprotective, anticonvulsant, anti-depressant:

AV-101, or its active metabolite 7-chlorokynurenic acid (7-Cl-KYNA), shows neuroprotective effects in animal models of excitotoxic neurotoxicity[4][5][6] anticonvulsant effects in animal models of epilepsy,[7][8] and depression,[1][9][10] and has been found to activate dopaminergic neurons.[11]

AV-101 is also a prodrug for 7-Cl-KYNA:

In vivo, AV-101 is converted into active 7-Cl-KYNA, one of the most potent and selective NMDAR glycine binding site antagonists,[4][6][15] and therefore, unlike classic NMDA receptor antagonists, such as keta…